Compare prices and buy PT-141 from 39 research peptide vendors - also called suppliers or sources. Updated daily.
A cyclic 7-amino-acid synthetic peptide (bremelanotide, CAS 189691-06-3), an alpha-MSH analog that matches Melanotan II except for a C-terminal carboxylic acid in place of an amide. A non-selective melanocortin receptor agonist: its FDA label gives the order of potency as MC1R, MC4R, MC3R, MC5R, MC2R, and states that the mechanism behind the approved indication is unknown. Approved by the FDA as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), developed by Palatin Technologies and now marketed by Cosette Pharmaceuticals.
For research purposes only. Not medical advice.
PT-141 is bremelanotide, a cyclic seven-amino-acid peptide, CAS 189691-06-3, molecular formula C50H68N14O10, molecular weight 1025.2. It is built on the alpha-melanocyte-stimulating hormone scaffold, and its nearest structural relative is Melanotan II.
The two differ at exactly one place. Melanotan II is C50H69N15O9 and bremelanotide is C50H68N14O10. One nitrogen has become an oxygen and one hydrogen is gone, the signature of a C-terminal amide converted to a carboxylic acid. That is the entire chemical difference, and it is checkable from the two PubChem records. Melanotan I is a different construction, a linear 13-residue analog.
Vendor pages, aggregators and AI-written summaries describe PT-141 as a selective MC3 and MC4 receptor agonist, redesigned to strip out Melanotan II's off-target activity. The prescribing information for the approved product says something else.
"Selective MC4 agonist" is not how the approved label characterizes the molecule.
Approval rested on two identical Phase 3 trials, protocols BMT-301 and BMT-302, published as the Reconnect studies and registered as NCT02333071 and NCT02338960. Each ran an eight-week baseline and a 24-week double-blind core phase against placebo.
Kingsberg and colleagues reported both in Obstetrics and Gynecology in 2019 (134:899-908) in a modified intent-to-treat population of 1,202 women. Against placebo, the desire score, which runs from 1.2 to 6.0, rose 0.30 points in study 301 and 0.42 in study 302, and the distress score fell 0.37 and 0.29 points. 684 patients continued into a 52-week open-label extension reported by Simon and colleagues in the same issue.
Those effects are contested. Spielmans and Ellefson, in the Journal of Sex Research in 2024, rated the validity evidence for the Reconnect efficacy measures questionable at best, and found effect sizes ranging from nil to small on eight registered outcomes that had not previously been published.
PT-141 holds a current United States approval. The FDA approved bremelanotide as Vyleesi under New Drug Application 210557 on June 21, 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The limitations of use are explicit: not for postmenopausal women, not for men, not to enhance sexual performance. It is the second of two drugs approved for that indication, after flibanserin, approved as Addyi in August 2015. Addyi's label was extended in December 2025 to women under 65 regardless of menopausal status, while Vyleesi's still excludes postmenopausal women.
The approval also puts PT-141 outside the regulatory arc that unapproved peptides in this index run on. BPC-157, Semax, Epitalon and their peers have no approved product, so their status turns on the Section 503A bulk drug substances list and the Pharmacy Compounding Advisory Committee. PT-141 has an approved application, and that is where its status is settled.
Palatin Technologies developed the compound, and Vyleesi is now marketed by Cosette Pharmaceuticals. Palatin ran a four-arm Phase 2 study of bremelanotide co-administered with tirzepatide in obesity (NCT06565611, planned enrollment 108), which reached primary completion in February 2025.
Vendors title the product PT-141 or bremelanotide, its generic name, and both resolve to this row.
Nasal sprays also appear in listings.
PeptideScouter indexes each format separately and prices per milligram, so a PT-141 vial is compared only against other PT-141 vials.
No, although it is often described that way. The FDA-approved prescribing information for Vyleesi describes bremelanotide as a melanocortin receptor agonist that nonselectively activates several receptor subtypes, and gives the order of potency as MC1R, MC4R, MC3R, MC5R, MC2R. MC1R, the pigmentation receptor, leads that order. MC4R is second in that order, and the label states that the mechanism by which the drug improves hypoactive sexual desire disorder is unknown. The label itself shows the MC1R activity is real: focal hyperpigmentation was reported in 1 percent of patients in the Phase 3 trials, and in 38 percent of patients after eight days of a separate study.
No. Vyleesi is a prescription drug product approved by the FDA under New Drug Application 210557 on June 21, 2019, and currently marketed by Cosette Pharmaceuticals. It is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and the label states explicitly that it is not indicated for postmenopausal women, not for men, and not to enhance sexual performance. The PT-141 sold by the vendors indexed here is research-grade material labeled for laboratory use only. It was not made under that approved application and carries none of its regulatory assurances.
Reconnect was the pair of identical Phase 3 studies behind the approval, protocols BMT-301 and BMT-302, registered as NCT02333071 and NCT02338960 with 1,267 women randomized across the two. Each ran an eight-week baseline followed by a 24-week double-blind placebo-controlled core phase. The co-primary endpoints were change in the desire domain of the Female Sexual Function Index and change in item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm. Kingsberg and colleagues reported both in Obstetrics and Gynecology in 2019 in a modified intent-to-treat population of 1,202 women. Against placebo, the desire score rose 0.30 points in study 301 and 0.42 in study 302, and the distress score fell 0.37 and 0.29 points.
PeptideScouter computes a per-milligram price only for listings measured in milligrams and sold as a vial. Nasal sprays are catalogued as their own format and excluded, because their price bundles a delivery device and a prepared solution rather than pricing peptide mass alone, so a per-milligram figure would not be comparable to a lyophilized vial. Spray listings still appear on this page with their vendor, size and price. They are simply left out of the per-milligram table and out of the lowest-per-milligram figures quoted elsewhere on the site.
PT-141 is sold by 39 research peptide vendors indexed on PeptideScouter, with 62 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
37 of the 39 indexed vendors currently have PT-141 in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Pepvida Labs currently lists PT-141 at $2.00/mg, the lowest listed price across 39 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.60/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 39 vendors listing PT-141 publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.00/mg listed to $1.60/mg at Pepvida Labs. Each vendor's code is shown beside its price in the table above.
PT-141 ranges from $2.00/mg to $8.80/mg across 62 listings from 39 research peptide vendors, normalized to USD per milligram and refreshed daily.
39 research peptide vendors currently list PT-141 on PeptideScouter, with 37 in stock right now. We track 62 listings across size and kit variants.
PT-141's CAS Registry Number is 189691-06-3. It is also sold as Bremelanotide, HLX-141, PT-141 (Bremelanotide).
